LYSAKARE (chlorhydrate de L-Arginine/ chlorhydrate de L-Lysine)

Key points

Favourable opinion for reimbursement for the reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (¹⁷⁷Lu) oxodotreotide in adults.

What therapeutic improvement?

No clinical added value compared to the hospital preparation.

Role in the care pathway?

During Peptide-Receptor Radionuclide Therapy (PRRT), the kidneys are exposed to high levels of radiation. The administration of a solution of 2.5% lysine and 2.5% arginine in 1 litre of 0.9% sodium chloride solution reduces the radiation dose administered to the kidney. Other solutions with a lysine and arginine content of 18 to 24 g can also be used, but these are more likely to cause nausea and vomiting due to their higher osmolarity and the larger volume administered.

Several learned societies recommend the co-administration of an amino acid solution in patients treated with PRRT in gastroenteropancreatic neuroendocrine tumours.

For any administration of LUTATHERA (lutetium (¹⁷⁷Lu) oxodotreotide), section 4.2 of the SPC specifies that co-administration of amino acid solutions is essential to protect renal function. In addition, an anti-emetic treatment should be administered 30 minutes before the start of the amino acid infusion to limit nausea and vomiting associated with this infusion.

Role of LYSAKARE (L-Arginine hydrochloride / L-Lysine hydrochloride) in the care pathway:

LYSAKARE is a first-line treatment for the reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (¹⁷⁷Lu) oxodotreotide.